Effect of IL-2 Therapy on CD8+ Cell Noncytotoxic Anti-HIV Response During Primary HIV-1 Infection

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2004 Mar 17

PMID 15024180

Citations 6

Authors

B Martinez-Marino

B M Ashlock

S Shiboski

F M Hecht

J A Levy

Affiliations

Soon will be listed here.

Abstract

Early treatment intervention during human immunodeficiency virus (HIV) infection is a strategy aimed to preserve and/or enhance the developing anti-HIV immune responses. We report the effect of highly active antiretroviral therapy (HAART) combined with intermittent subcutaneous doses of Interleukin 2 (IL-2) on CD8(+) cell noncytotoxic anti-HIV responses (CNAR), as well as on viral loads and CD4(+) cell/CD8(+) cell numbers in subjects with primary HIV-1 infection. Twenty-four patients received HAART, 24 received a combination of HAART plus IL-2, and 12 elected no-therapy. In comparison to HAART alone, IL-2 treatment led to significant increases in CD4(+) cell numbers through week 48 of the study. No effect was observed on viral loads or the CD8(+) cell population. The first cycle of IL-2 enhanced CNAR; later cycles showed no substantial effect. This study suggests that HAART combined with IL-2 could provide an immunologic benefit in the treatment of early HIV infection.

Citing Articles

The CD8 T Cell Noncytotoxic Antiviral Responses.

Morvan M, Teque F, Locher C, Levy J Microbiol Mol Biol Rev. 2021; 85(2).

PMID: 33980586 PMC: 8139528. DOI: 10.1128/MMBR.00155-20.

Vaginal innate immune mediators are modulated by a water extract of Houttuynia cordata Thunb.

Satthakarn S, Hladik F, Promsong A, Nittayananta W BMC Complement Altern Med. 2015; 15:183.

PMID: 26077233 PMC: 4466860. DOI: 10.1186/s12906-015-0701-9.

Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2.

Margolick J, Imteyaz H, Gallant J, Langan S, Dinoso J, Siliciano J AIDS. 2010; 24(6):932-5.

PMID: 20234195 PMC: 4565498. DOI: 10.1097/QAD.0b013e328333adfb.

Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival.

Martins G, Cimmino L, Liao J, Magnusdottir E, Calame K J Exp Med. 2008; 205(9):1959-65.

PMID: 18725523 PMC: 2526191. DOI: 10.1084/jem.20080526.

Primary human immunodeficiency virus type 1 infection.

Soogoor M, Daar E Curr HIV/AIDS Rep. 2005; 2(2):55-60.

PMID: 16091249 DOI: 10.1007/s11904-005-0019-1.

References

Kovacs J, Baseler M, Dewar R, Vogel S, Davey Jr R, Falloon J . Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med. 1995; 332(9):567-75. DOI: 10.1056/NEJM199503023320904. View

Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O . Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997; 175(5):1051-5. DOI: 10.1086/516442. View

Hecht F, Busch M, Rawal B, Webb M, Rosenberg E, Swanson M . Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002; 16(8):1119-29. DOI: 10.1097/00002030-200205240-00005. View

Barker E, Mackewicz C, Levy J . Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival. Proc Natl Acad Sci U S A. 1995; 92(24):11135-9. PMC: 40586. DOI: 10.1073/pnas.92.24.11135. View

Kinter A, Bende S, Hardy E, Jackson R, Fauci A . Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci U S A. 1995; 92(24):10985-9. PMC: 40555. DOI: 10.1073/pnas.92.24.10985. View

Davey Jr R, Chaitt D, Piscitelli S, Wells M, Kovacs J, Walker R . Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis. 1997; 175(4):781-9. DOI: 10.1086/513971. View

Dybul M, Hidalgo B, Chun T, Belson M, Migueles S, Justement J . Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis. 2002; 185(1):61-8. DOI: 10.1086/338123. View

Mackewicz C, Yang L, Lifson J, Levy J . Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet. 1994; 344(8938):1671-3. DOI: 10.1016/s0140-6736(94)90459-6. View

Simonelli C, Zanussi S, Sandri S, Comar M, Lucenti A, Talamini R . Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20(1):20-7. DOI: 10.1097/00042560-199901010-00003. View

10.

Mackewicz C, Barker E, Levy J . Role of beta-chemokines in suppressing HIV replication. Science. 1996; 274(5291):1393-5. DOI: 10.1126/science.274.5291.1393. View

11.

Lillo F, Ciuffreda D, Veglia F, Capiluppi B, Mastrorilli E, Vergani B . Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. AIDS. 1999; 13(7):791-6. DOI: 10.1097/00002030-199905070-00007. View

12.

Zajac A, Blattman J, Sourdive D, Suresh M, Altman J, Ahmed R . Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998; 188(12):2205-13. PMC: 2212420. DOI: 10.1084/jem.188.12.2205. View

13.

Janssen R, Satten G, Stramer S, RAWAL B, OBrien T, Weiblen B . New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998; 280(1):42-8. DOI: 10.1001/jama.280.1.42. View

14.

Soudeyns H, Campi G, Rizzardi G, Lenge C, Demarest J, Tambussi G . Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood. 2000; 95(5):1743-51. View

15.

Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux A . Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 2003; 17(3):343-51. DOI: 10.1097/00002030-200302140-00008. View

16.

Levy J, Mackewicz C, Barker E . Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today. 1996; 17(5):217-24. DOI: 10.1016/0167-5699(96)10011-6. View

17.

Levy J . HIV pathogenesis and long-term survival. AIDS. 1993; 7(11):1401-10. DOI: 10.1097/00002030-199311000-00001. View

18.

Musey L, Krieger J, Hughes J, Schacker T, Corey L, McElrath M . Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 1999; 180(2):278-84. DOI: 10.1086/314868. View

19.

Stranford S, Ong J, Martinez-Marino B, Busch M, Hecht F, Kahn J . Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A. 2001; 98(2):597-602. PMC: 14633. DOI: 10.1073/pnas.98.2.597. View

20.

Oxenius A, Price D, Easterbrook P, OCallaghan C, Kelleher A, Whelan J . Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000; 97(7):3382-7. PMC: 16248. DOI: 10.1073/pnas.97.7.3382. View